Thu, Nov 21, 2024
[Archive]
Volume 13, Issue 3 (7-2023)
Iran J Ped Hematol Oncol 2023, 13(3): 214-221 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yazdanparast M S, GHilian M M, Sheikhpour E. The Management and Approach to Osteosarcoma in Children: A Mini-review Article. Iran J Ped Hematol Oncol 2023; 13 (3) :214-221
URL: http://ijpho.ssu.ac.ir/article-1-790-en.html
URL: http://ijpho.ssu.ac.ir/article-1-790-en.html
Hematology and Oncology Research Center, Shahid sadoughi hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract: (719 Views)
Osteosarcoma (OS) is the most common type of primary malignant bone tumor. The onset of OS is associated with local pain and swelling as well as joint dysfunction, occasionally. The most common location for OS is around the knee joint. These patients often tend to receive medical attention following physical exercise and trauma. The affected population is mainly teenagers, children, and young adults with age range of 10-30 years.
OS can be diagnosed via different approaches. The main serum markers for pediatric OS are insulin‑like growth factor (IGF‑1 and IGFBP‑3), anti‑ki57 antibody, tumor necrosis factor (TNF)‑β and sTNF‑R, T3, CD44, vascular endothelial growth factor, serum amyloid A, CXC chemokines, bone alkalin phosphatase, Interleukin (IL‑2, IL‑4, IL‑8), interferon gamma (IFN-γ), TNF‑α, and free polyamines.
Given that there is no comprehensive review literature regarding OS management in our country, this study aimed to assess a survey on the management and approach of OS in children. In this regard, we have discussed the epidemiology, etiology, type, clinical feature, diagnosis, and OS therapy.
OS can be diagnosed via different approaches. The main serum markers for pediatric OS are insulin‑like growth factor (IGF‑1 and IGFBP‑3), anti‑ki57 antibody, tumor necrosis factor (TNF)‑β and sTNF‑R, T3, CD44, vascular endothelial growth factor, serum amyloid A, CXC chemokines, bone alkalin phosphatase, Interleukin (IL‑2, IL‑4, IL‑8), interferon gamma (IFN-γ), TNF‑α, and free polyamines.
Given that there is no comprehensive review literature regarding OS management in our country, this study aimed to assess a survey on the management and approach of OS in children. In this regard, we have discussed the epidemiology, etiology, type, clinical feature, diagnosis, and OS therapy.
Type of Study: Review |
Subject:
General
Received: 2023/03/21 | Accepted: 2023/06/29 | Published: 2023/07/19
Received: 2023/03/21 | Accepted: 2023/06/29 | Published: 2023/07/19
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
